#China #Guangzhou #healthcare #ADS Ratio #POMDOCTOR

POMDOCTOR LIMITED's ADS Ratio Change Announcement

POMDOCTOR LIMITED, listed on NASDAQ under the symbol POM, is a prominent online medical services provider in China, specializing in chronic disease management. On May 28, 2026, the company unveiled its intention to implement a significant change in the ratio of its American Depositary Shares (ADS) concerning its Class A ordinary shares. As part of this adjustment, the existing ratio of one ADS representing one-sixth of a Class A ordinary share will shift to a new ratio where one ADS will represent three Class A ordinary shares.

This strategic move can be likened to a reverse ADS split of one-for-eighteen, which means that shareholders will see their current holdings transformed into a different configuration, enhancing the overall value of their shares in an effective manner. This modification is expected to take effect on or around June 22, 2026, dependent on regulatory approvals from the U.S. Securities and Exchange Commission (SEC) regarding the post-effective amendment to the ADS Registration Statement on Form F-6.

For holders of ADSs within the Direct Registration System (DRS) and those in The Depository Trust Company (DTC), the conversion will happen automatically, removing the need for any action on their part. Each shareholder will receive one newly issued ADS for every eighteen existing ADSs they hold on the Effective Date, with existing ADSs being canceled accordingly. Citibank, N.A., which serves as the depositary bank for POMDOCTOR’s ADS program, will manage the entire exchange process.

Importantly, it should be noted that fractional new ADSs will not be issued as a result of the ADS Ratio Change. Instead, any fractional entitlements will be aggregated and sold by the depositary bank, with the net proceeds—after accounting for taxes and fees—distributed back to the respective ADS holders. This change exclusively affects the ADSs, leaving the underlying Class A ordinary shares untouched.

As the modification aims to enhance the trading price of the ADSs, it is projected that the value will increase proportionately upon the adjustment’s effectiveness. Nonetheless, the company cautioned that there is no definitive guarantee that the post-change trading price will reach or exceed eighteen times the value prior to the ADS Ratio Change.

Additionally, the deposit agreement established with the bank on October 9, 2025, will also be amended to reflect this significant ratio change.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED stands out as one of China’s most influential online platforms focusing on medical services for chronic illnesses. According to a report by Frost & Sullivan in 2022, the company proudly ranks sixth in China's Internet hospital market based on its number of contracted physicians. The firm is dedicated to integrating patients with healthcare providers and pharmaceutical services, aiming to streamline the experience through a comprehensive digital platform. POMDOCTOR’s overarching mission is to deliver effective treatment solutions while striving to enhance the healthcare value chain’s efficiency and transparency.

With a vision to be a trusted source for medical and healthcare services, POMDOCTOR continues to set a benchmark in chronic disease management. For additional details, please visit their official site at http://ir.7shiliu.com.

Forward-Looking Statements

While the company expresses optimism regarding its future trajectory, it acknowledges the inherent risks in forward-looking statements. Investors are encouraged to consider these uncertainties and refer to the comprehensive filings available at the SEC for further insights into factors that may influence the company’s future performance. For inquiries, their Investor Relations Department can be contacted via email at [email protected] or by calling Ascent Investor Relations LLC at +1-646-932-7242.